Apixaban for Heart Failure
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.
Who Is on the Research Team?
Nir Uriel, MD
Principal Investigator
New York Presbyterian / Columbia University Medical Center
Are You a Good Fit for This Trial?
This trial is for adults (18+) with advanced heart failure who have had a HeartMate 3 LVAD implanted for over 3 months and are currently taking warfarin. Participants must not be pregnant and must agree to use contraception if they can become pregnant.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Apixaban
- Warfarin
Trial Overview
The study compares two blood thinners, apixaban and warfarin, to see which better prevents blood clots and bleeding in people with a HeartMate 3 LVAD. Participants are randomly assigned to one of the treatments.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants wil take apixaban 5 mg bid
Participants will take warfarin, dose titrated for an INR \>= 1.8
Find a Clinic Near You
Who Is Running the Clinical Trial?
Columbia University
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.